Coeptis, Inc., a pioneering technology company focused on AI-driven biotech solutions, has successfully closed an additional $5.7 million in its final Series A Preferred Offering, bringing the total financing round to $10 million. This milestone underscores strong investor confidence in Coeptis’ strategic pivot toward technology-driven growth and innovative therapeutic solutions.
The latest financing was led by CJC Investment Trust, an entity controlled by board member Christopher Calise, who increased their initial investment in the round. Investors also received a 15% equity interest in Coeptis’ newly formed subsidiaries, SNAP Biosciences Inc. and GEAR Therapeutics Inc.
Highlights of the Financing Round
- Total Funds Raised: $10 million
- Final Closure Amount: $5.7 million
- Lead Investor: CJC Investment Trust
- Conversion Terms: Series A Preferred convertible into common stock at $8.00 per share
- Equity Distribution: Investors received a 15% stake in SNAP Biosciences Inc. & GEAR Therapeutics Inc.
Strategic Use of Funds
Coeptis plans to leverage this capital to:
- Strengthen Financial Position: Enhance the company’s balance sheet and repay outstanding obligations.
- Expand AI Integration: Accelerate the adoption of AI-driven tools, particularly from the NexGenAI Affiliates Network platform, to optimize marketing and operational efficiencies.
- Enhance Biotech Innovation: Support research and automation advancements in cell therapy and biopharmaceutical solutions.
- Drive Sustainable Growth: Establish a self-sustaining business model with long-term profitability.
Leadership Perspectives
- Brian Cogley, CFO of Coeptis:
“This funding is pivotal as we expand operational capabilities and enhance shareholder value through our new Technology Division. AI-driven tools will revolutionize our approach to marketing and operational efficiencies.” - Dave Mehalick, President & CEO of Coeptis:
“This financing enables us to fortify our mission in cell therapy while driving innovation in AI and technology. Our goal is to foster responsible innovation and capitalize on diverse growth opportunities.”
Conclusion
The successful closure of Coeptis’ Series A financing marks a significant step in its evolution as a leader in AI-driven biotechnology. With strengthened financial resources and a clear focus on AI-powered advancements, Coeptis is poised to revolutionize therapeutic research, operational efficiencies, and long-term industry growth.
